乳腺癌组织中P-gp、GST-π与TopoⅡ耐药基因的表达及临床意义  

Expression of P-gp, GST-π and Topo Ⅱ in breast carcinoma tissue and their Clinical significance

作　　者：刘晓霞[1] 王岩[1] 张少华[1] 毕晓芳[1] 陈利平[1] 方虹[1] 贾支红 柳春晖[1] 

机构地区：[1]宁夏银川市第一人民医院,宁夏银川750001

出　　处：《宁夏医学杂志》2006年第7期489-491,F0002,共4页Ningxia Medical Journal

摘　　要：目的探讨多药耐药基因蛋白P-糖蛋白(P-gp)、谷胱甘肽-S-转移酶-π(GST-π)及DNA拓扑异构酶Ⅱ(TopoⅡ)在乳腺癌中的表达及其临床意义。方法用免疫组化法检测52例未经抗肿瘤治疗的原发乳腺癌中P-gp、GST-π及TopoⅡ的表达水平。结果52例乳腺癌组织中P-gp、GST-π和TopoⅡ表达率分别为57.7%、53.8%和76.9%,P-gp、GST-π和TopoⅡ的表达与组织学类型、年龄无关(P>0.05),与临床分期、淋巴结转移有显著性差异(P<0.05),P-gp和GST-π的表达呈显著正相关(P<0.05),P-gp和TopoⅡ的表达呈明显负相关(P<0.05),GST-π和TopoⅡ呈明显负相关(P<0.05)。结论乳腺癌化疗前检测P-gp、GST-π及TOPOⅡ耐药基因蛋白,对肿瘤的化疗药物选择及判断预后有一定的价值。Objective To explore the expression and clinical significance of P-giycoprotein（P-gp）, Glutathione- s- transferase -π（GST-π） and Topo Ⅱ in breast carcinoma tissue. Methods The expression level of P-gtycoprotein （P-gp）, Glutathione- s-transferase - π（GST-π）and Topo Ⅱ in the operating samples from 52 cases with with untreated primary breast carcinomas were detected with immunohistochemical method. Results Positive expression rates of P-gp, GST-π and Topo Ⅱin 52 cases of hreast carcinoma were 57.7%（30/52）, 53.8 % （28/52） and 76.9 % （40/52）. The positive expression of P - gp, GST-π and Topo Ⅱ was no relationship with histological type and patients＇ age （ P 〈 0.05 ）, and which was significant associated with dinical stage and lymph node metasis（ P 〈 0.05） . P - gp significantly positively correlation with GST-π（ P 〈0.05）, P-gp negativdy related to Topo Ⅱ （ P 〈0.05）, GST- π had obvionsly negative corrdation with Topo Ⅱ （ P 〈 0.05）. Conclusion Before chemotherapy to patients with breast carcinoma, the test of resistance drug gene will help doctors select the mechanisms of drug and to evaluate prngnosis of breast carcinoma.

关 键 词：乳腺癌 P-糖蛋白 谷胱甘肽-S转移酶 DNA拓扑异构酶Ⅱ 

分 类 号：R737.9[医药卫生—肿瘤]